All In Biotech

NDA 210607 · 60 Degrees Pharms

Arakoda

Tafenoquine Succinate · Oral

Priority review

Last checked: Nov 19, 2026Latest source record: Feb 25, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Aug 8, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

39

7 Phase 3, 8 recruiting

FAERS reports

66

57 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 10, 2025.

ARAKODA is indicated for the prophylaxis of malaria in patients aged 18 years and older. ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. ( 1 )

Mechanism: Tafenoquine is an 8-aminoquinoline antimalarial drug [see Microbiology ( 12.4 )] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 8, 2018 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LabelLetterReview
1 products under this application
  • ARAKODA · TAFENOQUINE SUCCINATE EQ 100MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tafenoquine" as an intervention, any sponsor and status, largest first.

All 39 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • depression20
  • anxiety18
  • nausea15
  • post-traumatic stress disorder15
  • anger14
  • tinnitus12
  • headache11
  • dizziness10
  • memory impairment10
  • mental disorder10
  • off label use10
  • paranoia10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20061
20071
201823
20195
20202
20212
20222
202311
20248
20253
20268

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 53 on PubMed

Sponsor: 60 Degrees Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.